Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Interpace Biosciences's Enterprise Value is €36.09 Mil.
Interpace Biosciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €3.47 Mil. Therefore, Interpace Biosciences's EV-to-EBIT ratio for today is 10.42.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Interpace Biosciences's Enterprise Value is €36.09 Mil.
Interpace Biosciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €4.23 Mil. Therefore, Interpace Biosciences's EV-to-EBITDA ratio for today is 8.53.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Interpace Biosciences (STU:PF42) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Interpace Biosciences's current Enterprise Value is €36.09 Mil.
Interpace Biosciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.47 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Interpace Biosciences's EV-to-EBITDA for today is:
Interpace Biosciences's current Enterprise Value is €36.09 Mil.
Interpace Biosciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.23 Mil.
Interpace Biosciences's current Enterprise Value is €36.09 Mil.
Interpace Biosciences's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €31.08 Mil.
Interpace Biosciences's current Enterprise Value is €36.09 Mil.
Interpace Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.81 Mil.
Interpace Biosciences's current Enterprise Value is €36.09 Mil.
Interpace Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences Enterprise Value Related Terms
Interpace Biosciences Enterprise Value Historical Data
* Premium members only.
The historical data trend for Interpace Biosciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PF42 vs PRPO, ADVB, BIOQ: Enterprise Value Comparison
For the Diagnostics & Research subindustry, Interpace Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interpace Biosciences Enterprise Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's Enterprise Value falls into.
Interpace Biosciences Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Interpace Biosciences's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences (STU:PF42) has a Enterprise Value of €36.09 Mil as of Aug. 20, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Interpace Biosciences and its competitors.
Is Interpace Biosciences' Enterprise Value too high?
Interpace Biosciences' current Enterprise Value is €36.09 Mil. Overall, Interpace Biosciences has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' Enterprise Value compare to PRPO and ADVB?
Interpace Biosciences' Enterprise Value of €36.09 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Diagnostics & Research company?
A good Enterprise Value depends on the Medical Diagnostics & Research industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Interpace Biosciences and its competitors. Interpace Biosciences's current Enterprise Value is €36.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Interpace Biosciences (STU:PF42) has a current Enterprise Value of €36.09 Mil. The stock's GF Value™ is €0.17, compared to a current price of €1.34 — trading 688.2% above its estimated fair value. The current Enterprise Value is €36.09 Mil. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Interpace Biosciences (STU:PF42), the current Enterprise Value is €36.09 Mil as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (STU:PF42) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of €1.34 is trading 688.2% above its estimated GF Value™ of €0.17.
Key valuation signals for STU:PF42:
Enterprise Value: €36.09 Mil
GF Value™: €0.17 vs. price of €1.34 (688.2% above fair value)
No single metric tells the full story. See the STU:PF42 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for STU:PF42
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PF42 has been successfully added to your 
